Harnessing The Power of Selective Targeting of Toxic Oligomers to Combat Neurodegenerative Diseases and other Misfolded Protein Diseases
ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. Using our proprietary target discovery engine, EpiSelect™, we can predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s Disease (PD). We have offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).